354 related articles for article (PubMed ID: 19208845)
1. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
2. Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.
Jing Y; Chavez V; Ban Y; Acquavella N; El-Ashry D; Pronin A; Chen X; Merchan JR
Mol Cancer Res; 2017 Oct; 15(10):1410-1420. PubMed ID: 28679779
[TBL] [Abstract][Full Text] [Related]
3. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
4. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic measles virus retargeting by ligand display.
Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
[TBL] [Abstract][Full Text] [Related]
6. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy.
Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E
J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity by dual stromal and tumor-targeted oncolytic measles viruses.
Jing Y; Chavez V; Khatwani N; Ban Y; Espejo AP; Chen X; Merchan JR
Cancer Gene Ther; 2020 Dec; 27(12):910-922. PubMed ID: 32231231
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E
Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158
[TBL] [Abstract][Full Text] [Related]
11. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
Allen C; Vongpunsawad S; Nakamura T; James CD; Schroeder M; Cattaneo R; Giannini C; Krempski J; Peng KW; Goble JM; Uhm JH; Russell SJ; Galanis E
Cancer Res; 2006 Dec; 66(24):11840-50. PubMed ID: 17178881
[TBL] [Abstract][Full Text] [Related]
12. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
Paraskevakou G; Allen C; Nakamura T; Zollman P; James CD; Peng KW; Schroeder M; Russell SJ; Galanis E
Mol Ther; 2007 Apr; 15(4):677-86. PubMed ID: 17299404
[TBL] [Abstract][Full Text] [Related]
14. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
[TBL] [Abstract][Full Text] [Related]
15. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
17. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
[TBL] [Abstract][Full Text] [Related]
18. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
Ayala-Breton C; Barber GN; Russell SJ; Peng KW
Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.
Li H; Peng KW; Dingli D; Kratzke RA; Russell SJ
Cancer Gene Ther; 2010 Aug; 17(8):550-8. PubMed ID: 20379224
[TBL] [Abstract][Full Text] [Related]
20. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]